Nivolumab plus relatlimab for advanced melanoma in India
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests a combination of two immunotherapy drugs, nivolumab and relatlimab, for people with melanoma that cannot be removed by surgery or has spread. The treatment aims to help the immune system fight the cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have melanoma that has spread or cannot be removed by surgery.
- You must be able to perform daily activities with some help (ECOG score 0-2).
- You must have at least one tumor that can be measured on a CT or MRI scan.
- If you had radiation therapy, it must have been completed at least 2 weeks before starting the study.
- You must not be pregnant or breastfeeding.
- You must not have active brain metastases, uveal melanoma, or an active autoimmune disease requiring treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a second immunotherapy drug (ipilimumab) to the standard first-line combo of nivolumab and relatlimab improves outcomes for advanced melanoma. It uses a blood test (ctDNA) to decide who gets the extra drug.
This trial tests a new drug (iSCIB1+) combined with two standard immunotherapy drugs (ipilimumab and nivolumab) as the first treatment for advanced melanoma that cannot be removed by surgery. The goal is to see if adding iSCIB1+ helps the immune system fight the cancer better.
This study tests how well immunotherapy drugs like pembrolizumab and nivolumab work for people with advanced melanoma that has spread. It aims to find markers that predict treatment response.
This trial tests a combination of liver-directed chemotherapy (HEPZATO KIT) with a new immunotherapy called Opdualag for people whose melanoma has spread to the liver and who have not had many prior treatments.
This Phase 2 study tests whether nivolumab plus relatlimab can shrink or control melanoma that has spread to the brain. It may help by boosting the immune system to attack the cancer, including melanoma in brain areas that can’t be treated with prior focused radiation.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
Hear when a new Unresectable Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.